title: Prevalence of Antidiabetic and Antilipidemic Medications in Children and Adolescents Treated With Atypical Antipsychotics in a Virginia Medicaid Population.
abstract: Atypical antipsychotic use among children and adolescents is a cause for concern secondary to metabolic adverse effects. There have been reports of weight gain, metabolic syndrome, dyslipidemia, glucose abnormalities, and decreased insulin sensitivity in children aged 4 to 19 years using atypical antipsychotics.
  
  
  
  To determine the prevalence of antidiabetic and antilipidemic medication use among children and adolescents receiving atypical antipsychotics and to evaluate whether the odds of receiving antidiabetic and antilipidemic medication differs among atypical antipsychotic agents.
  
  
  
  This retrospective cross-sectional study included Virginia Medicaid beneficiaries (2-17 years) continuously enrolled from August 1, 2010, to July 31, 2011. The participants were categorized into atypical antipsychotic exposed and unexposed. The prevalence of antidiabetic and antilipidemic medication use within the groups was computed. Logistic regression was used to calculate the odds of receiving antidiabetic or antilipidemic medication after controlling for age, sex, and race.
  
  
  
  A total of 299593 and 4922 beneficiaries were identified in unexposed and exposed groups, respectively. The prevalence of antidiabetic medication use was 0.32% in the unexposed and 1.40% in the exposed group (P < 0.0001). Prevalence of antilipidemic medication use was 0.09% in the unexposed and 0.35% in the exposed group (P < 0.0001). Risperidone and quetiapine users had lower odds than olanzapine users of receiving antidiabetic medication. No differences between the odds of receiving antilipidemic medication among the different antipsychotics (P = 0.1653) were observed.
  
  
  
  Prevalence of antidiabetic and antilipidemic medication use was significantly higher among children and adolescent atypical antipsychotic users in a Virginia Medicaid population.
authors.affiliation: Virginia Commonwealth University, VA, USA.
authors.forename: Della
authors.initials: D
authors.lastname: Varghese
authors.affiliation: Virginia Commonwealth University, VA, USA ckkirkwo@vcu.edu.
authors.forename: Cynthia K
authors.initials: CK
authors.lastname: Kirkwood
authors.affiliation: Virginia Commonwealth University, VA, USA.
authors.forename: Norman V
authors.initials: NV
authors.lastname: Carroll
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008484:Medicaid; D024821:Metabolic Syndrome / Q000453:epidemiology / Q000517:prevention & control*; D017891:Pharmacoepidemiology; D015995:Prevalence; D012189:Retrospective Studies; D014481:United States; D014768:Virginia; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents
keywords: adolescents; antidiabetic medications; antilipidemic medications; atypical antipsychotics; children; pharmacoepidemiology